Loading…
VASRAN XL is a brand name for Alfuzosin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Treatment of moderate to severe functional symptoms of benign prostate hyperplasia (BPH). As an adjunct therapy in connection with catheterisation in acute urinary retention (AUR) related to BPH.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology BPH:
The recommended dose is one Alfuzosin 10 mg prolonged-release tablet to be taken once daily after the evening meal.
AUR:
One 10 mg tablet daily after a meal to be taken from the first day of catheterisation and continued beyond catheter removal unless there is a relapse of acute urinary retention or disease progression. Elderly (over 65 years) and patients with renal impairment Based on pharmacokinetic and clinical safety data, older people and patients with renal insufficiency (creatinine clearance ≥30 ml/min) can be treated with the usual dose.
Due to lacking clinical safety data. 4).
Hepatic insufficiency:
Alfuzosin, given as 10 mg prolonged-release tablets are contraindicated in patients with hepatic insufficiency. Preparations containing a low dose of alfuzosin hydrochloride might be used in patients with mild to moderate hepatic insufficiency as instructed in the corresponding product information.
Therefore, Alfuzosin is not indicated for use in paediatric population. Method of administration For oral use. g. a glass of water). 4).
4) Atrial fibrillation Vascular disorders Hypotension (postural), flushing Respiratory, thoracic and mediastinal disorders Rhinitis Gastrointestinal disorders Nausea, abdominal pain, dry mouth Diarrhoea Vomiting Hepatobiliary disorders Hepatotoxicity Hepatocellular injury, cholestatic liver disease.
4) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.
The patient should be examined before commencement of therapy with alfuzosin to exclude the presence of other conditions that can produce similar symptoms to those of BPH. Before starting and regularly during treatment, examination with rectal touch and, if necessary, prostate specific antigen (PSA) should take place.
Care should be taken when alfuzosin is administered to patients who have had a pronounced hypotensive response to another alpha-1-receptor blocker. Alfuzosin should be given with caution to patients who are being treated with antihypertensive medications or nitrates.
Blood pressure should be monitored at the start of treatment. 8). Elderly patients (especially the patient over 75 years of age) and patients receiving medication for cardiovascular disease are at the greatest risk of (orthostatic) hypotension.
Blood pressure should be carefully monitored in these patients. In some subjects postural hypotension with or without symptoms (dizziness, fatigue, sweating) may develop within a few hours following administration. In such cases the patient should rest lying down until the symptoms have completely disappeared.
These effects are transient, occur at the start of the treatment and usually do not require the treatment to be stopped. The patient should be warned that these symptoms may possibly occur. In coronary patients the specific treatment for coronary insufficiency should be continued.
If angina pectoris recurs the treatment with alfuzosin should be discontinued. As with all alpha-1-receptor blockers alfuzosin should be used with caution in patients with acute cardiac failure. Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of alfuzosin.
5). g. itraconazole and clarithromycin) and a temporary interruption of alfuzosin treatment is recommended if treatment with such medicinal products is initiated. The ’Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin.
1 - History of orthostatic hypotension - Combination with other alpha-1 receptor blockers - Hepatic insufficiency.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Alfuzosin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Isolated reports have also been received with other alpha-1-blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during the cataract operation, current or past use of alpha-1-blockers should be made known to the ophthalmic surgeon in advance of surgery.
Like other alpha-1-receptor blockers, alfuzosin is associated with priapism. If not treated properly, this side effect may lead to permanent tissue damage (including necrosis and/or gangrene) and impotence. If priapism occurs, the patient should seek immediate medical assistance to determine the severity of the side effect and the need for observation and/or treatment.
g. 5). To reduce the risk of developing orthostatic hypotension, patients should be stabilized on alpha- blocker therapy before initiating therapy with a phosphodiesterase-5 inhibitor. In addition, it is recommended to start treatment with a phosphodiesterase-5 inhibitor at the lowest possible dose.
Patients should be warned that the tablet should be swallowed whole. Other methods of administration such as crunching, crushing, grinding, pounding to powder or chewing the tablets should be prohibited. These actions may lead to inappropriate release and absorption of the drug with the risk of early side effects.
As there are no clinical safety data available in patients with severe renal impairment (creatinine clearance < 30ml/min), Alfuzosin 10 mg prolonged-release tablets should not be administered to this patient group. This product contains lactose.
Patients with rare hereditary conditions such as galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.